Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
about
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesMolecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.JAK2V617F allele burden in patients with myeloproliferative neoplasms.Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.
P2860
Q33514281-61CFBD75-9A8C-4E8B-8746-DE6802E45C4DQ33829070-28FEBA53-712D-4124-AFF5-A25EC991831CQ34478126-0047455E-0DDF-4A5A-889C-E4E4F67898D0Q35132241-143B0FFF-22CA-4822-AD3D-02B8A6E9C4E8Q36153557-4EC03FAF-D03A-4CD2-8E10-4E5F36BC06E2Q36851400-9047ED76-5C8B-41F7-A470-03AF9FCB8839Q37379320-85076D02-93C0-49A7-8842-38B40C35DC9CQ37460337-44784FCB-7E07-4458-8AD4-2A1368ED9133Q38027835-8A7A2D18-03B2-4853-8E2B-D2755D7A5A30Q38400828-3C8E7652-8422-488F-B483-EC1449A6827AQ39240059-CABD10FD-368D-4396-84DF-92FBC3B32681Q39300448-6D88CB7A-8068-403E-874D-9F7387132CB7Q43122604-B2492585-2066-4F59-98BF-98BA705DE006Q44628031-5B92802C-CEB7-46EC-AC9D-69F218850404Q51781540-A6B17FD6-6487-4A8A-8BCE-806C909F7A94Q52887806-64EF70EC-107D-46E4-9D25-DEA6A5D09929
P2860
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@ast
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@en
type
label
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@ast
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@en
prefLabel
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@ast
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@en
P2093
P2860
P356
P1433
P1476
Comparison of mutated ABL1 and ...... n myeloproliferative disorders
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2008.133
P577
2008-06-05T00:00:00Z